Secondary Oligo-Asthenoteratospermia After Sleeve Gastrectomy: A Case Report

2021 ◽  
Vol 15 (9) ◽  
pp. 2984-2985
Author(s):  
Syeda Nazia Kulsum ◽  
Ali Faraz ◽  
Kauser Fathima ◽  
Kashif Shaikh ◽  
Nazia Khan ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Sleeve Gastrectomy ◽  
Case Report ◽  
Key Words ◽  
Semen Analysis ◽  
Semen Parameters ◽  
Weight Loss Treatment ◽  
Surgical Operations

Sleeve gastrectomy (SG) is a relatively recent and effective weight-loss treatment. Because the number of bariatric surgical operations is increasing, surgeons should be aware of the issues related with SG. In the absence of an identifiable etiology, oligo-asthenoteratospermia in a patient with proven fertility is unusual. Here we describe a case of severe worsening of semen parameters after SG. Key words: Key words: Sleeve gastrectomy, Bariatric surgery , Semen analysis

scholarly journals A novel description of converting a gastric plication to sleeve gastrectomy for weight loss: A case report

2021 ◽  
pp. 105972
Author(s):  
Jonathan R. Chino ◽  
Garrett JonesDO ◽  
Amit B. Karmur ◽  
Robert Stowe ◽  
Barry Sanchez
Keyword(s):  
Weight Loss ◽  
Sleeve Gastrectomy ◽  
Case Report ◽  
Gastric Plication

scholarly journals Sleeve Gastrectomy vs. Fundus Resection in Bariatric Surgery (Animal Study)

2020 ◽  
Vol 21 (6) ◽  
Author(s):  
Alimohammad Bananzadeh ◽  
Seyed Vahid Hosseini ◽  
Hajar Khazraei ◽  
Mohammad Mehdi Lashkarizadeh ◽  
Leila Ghahramani ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Sleeve Gastrectomy ◽  
Body Weight Loss ◽  
Test Results ◽  
Significant Difference ◽  
Before And After ◽  
Total Ghrelin ◽  
The Difference ◽  
High Level

Background: Bariatric surgery has resulted in body weight loss, which claimed by surgery removal specific parts of the stomach with enzyme or sleeve gastrectomy. Objectives: The aim of this study is to determine weight loss and endocrine changes by 12-week fundus resection and sleeve gastrectomy in rabbits. Methods: Twenty-one rabbits, weighing 2.5 - 3.5 kg, were divided into three groups (n = 7): sleeve gastrectomy, experimental fundus resection, and sham group. The weight of rabbits and total ghrelin and leptin levels in the plasma before and after surgery were measured in 12 weeks. Statistical analyses were performed using the Kruskal-Walis test for comparison of the means between the groups, and the difference after months in one group was assayed by Friedman test. Results: The results showed sleeve gastrectomy had a significant weight loss after one month when compared to fundus resection and sham-operated controls (P = 0.008). There was no significant difference in the ghrelin levels after these surgeries, but leptin levels decreased significantly after the fundectomy (P = 0.025). Conclusions: Sleeve gastrectomy is more efficient than the fundus resection in weight loss. It could be suggested as a new option in metabolic disorders due to the high level of leptin.

scholarly journals Lithium toxicity following bariatric surgery

2020 ◽  
Vol 8 ◽  
pp. 2050313X2095300 ◽  
Author(s):  
Suzanna Connick Jamison ◽  
Kelley Aheron
Keyword(s):  
Bariatric Surgery ◽  
Morbid Obesity ◽  
Weight Loss ◽  
Sleeve Gastrectomy ◽  
Laparoscopic Sleeve Gastrectomy ◽  
Therapeutic Range ◽  
Lithium Therapy ◽  
Lithium Toxicity ◽  
Psychiatric Comorbidities ◽  
Monitoring Protocol

A patient with morbid obesity and several psychiatric comorbidities underwent laparoscopic sleeve gastrectomy and experienced success with weight loss. However, she experienced lightheadedness, nausea, and a fall and was admitted to the hospital for encephalopathy due to lithium toxicity. The pharmacokinetics of lithium is altered following bariatric surgery. Due to these factors, adjustments were made to the patient’s lithium therapy, her levels were subsequently reduced into the therapeutic range, and she continued with no further issues. Mechanisms of lithium toxicity following bariatric surgery and a monitoring protocol to prevent toxicity are discussed.

scholarly journals Quality of Life before and after Sleeve Gastrectomy in Lebanese Population

2019 ◽  
Vol 2019 ◽  
pp. 1-6
Author(s):  
Marwan Alkassis ◽  
Fady Gh Haddad ◽  
Joseph Gharios ◽  
Roger Noun ◽  
Ghassan Chakhtoura
Keyword(s):  
Quality Of Life ◽  
Bariatric Surgery ◽  
Weight Loss ◽  
Sleeve Gastrectomy ◽  
Sexual Pleasure ◽  
Life Questionnaire ◽  
Before And After ◽  
The Mean ◽  
The Impact

Introduction. Obesity is increasing worldwide and in Lebanon with a negative impact on the quality of life. The primary objective of this study is to measure the quality of life in obese subjects before and after bariatric surgery, depending on age, sex, and degree of weight loss. A secondary objective is to determine the impact of bariatric surgery on comorbidities associated with obesity. Materials and methods. Patients undergoing laparoscopic sleeve gastrectomy for BMI ≥ 30 kg/m2 between August 2016 and April 2017 were included. Participants completed the Moorehead-Ardelt Quality of Life Questionnaire II (MA II) prior to operation and one year after. Statistical analysis was carried out using SPSS statistics version 20.0. Results. 75 patients participated in the study. The majority were women (75%), and the mean age was 36.3 years. The mean weight loss was 36.57 kg (16–76). Initially, the total MA II score was −0.33 ± 0.93. Postoperatively, it increased to 1.68 ± 0.62 (p≤0.001). All MA II parameters improved after surgery (p≤0.001), but this improvement was independent of age and sex. Improvement in self-esteem, physical activity, work performance, and sexual pleasure was influenced by the degree of weight loss (p≤0.001). All comorbidities associated with obesity regressed significantly after sleeve gastrectomy (p<0.05) with the exception of gastroesophageal reflux and varicose veins of the lower limbs. Conclusion. Sleeve gastrectomy improves quality of life and allows reduction of comorbidities.

Institutional Improvement in Weight Loss after Laparoscopic Sleeve Gastrectomy

2016 ◽  
Vol 82 (5) ◽  
pp. 448-455
Author(s):  
Christopher W. Mangieri ◽  
Matthew A. Strode ◽  
William E. Sherman ◽  
Matthew L. Pierotti ◽  
Byron J. Faler ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Sleeve Gastrectomy ◽  
Laparoscopic Sleeve Gastrectomy ◽  
Body Weight Loss ◽  
Excess Body Weight ◽  
Institutional Improvement ◽  
Body Mass Index Loss ◽  
Institutional Experience ◽  
Collective Experience

Laparoscopic sleeve gastrectomy (LSG) is a recent addition to the bariatric surgery armamentarium. It has been demonstrated to be an efficacious stand-alone bariatric procedure in regard to weight loss. This study evaluates the progress of our initial experience with LSG. Retrospective review of prospective data from 2008 to 2010. Compared data between our first operative year of experience with LSG (2008) and our third year of experience (2010). Data compared for up to three years postoperatively. End points were percentage of excess body weight loss (%EWL) and percentage of excess body mass index loss (%EBL). Institutional improvement in %EWL and %EBL rates as our collective experience increased with LSG. Mean increase in %EWL of 14 per cent and mean increase of %EBL of 22 per cent. In our first year performing LSG the institutional weight loss was <50 per cent EWL, which is often cited as a benchmark level for “success” after bariatric surgery. By our third year of experience with LSG we achieved an institutional weight loss >50 per cent EWL. Institutional improvement in weight loss results with LSG as the collective experience increased. Several factors could have contributed to this observation to include a surgical men-torship program and the institution of formal nutritional education. This study demonstrates that institutional experience is a significant factor in weight loss results with LSG.

scholarly journals Case Report of Increased Exposure to Antiretrovirals following Sleeve Gastrectomy

2020 ◽  
Vol 64 (4) ◽  
Author(s):  
Sarah Israel ◽  
Hila Elinav ◽  
Ram Elazary ◽  
Daniel Porat ◽  
Roni Gibori ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Sleeve Gastrectomy ◽  
Case Report ◽  
Therapeutic Drug Monitoring ◽  
Drug Exposure ◽  
Therapeutic Drug ◽  
Morbidly Obese ◽  
Limited Data ◽  
Time Points ◽  
Antiretroviral Drug

ABSTRACT Bariatric surgery is increasingly performed in morbidly obese HIV patients. Limited data exist regarding antiretroviral drug exposure after bariatric surgery. We report a case of a morbidly obese HIV patient who underwent sleeve gastrectomy. Abacavir, lamivudine, and dolutegravir therapeutic drug monitoring was performed at several time points pre- and postsurgery. Significantly increased levels were measured, particularly for abacavir, whose levels increased ∼12-fold. Several mechanistic explanations for these findings are discussed.

scholarly journals Changes in quality of life 5 years after sleeve gastrectomy: a prospective cohort study

BMJ Open ◽  
2019 ◽  
Vol 9 (9) ◽  
pp. e031170 ◽  
Author(s):  
Tone Nygaard Flølo ◽  
Grethe S Tell ◽  
Ronette L Kolotkin ◽  
Anny Aasprang ◽  
Tone Merete Norekvål ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Bariatric Surgery ◽  
Weight Loss ◽  
Cohort Study ◽  
Sleeve Gastrectomy ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Short Form

ObjectivesSleeve gastrectomy (SG) is the most frequently performed bariatric surgery procedure worldwide, but reports on long-term quality of life (QOL) outcomes are scarce. We investigated 5-year trajectories in QOL and their associations with weight loss after SG.DesignA prospective cohort study.SettingThe study was conducted in a single Norwegian bariatric surgery centre.ParticipantsOut of 150 operated patients, 127 were included. Mean age was 41 years, 68% were women and the follow-up rate at 1 year was 85% and 64% at 1 and 5 years, respectively.Outcome measuresData were collected preoperatively, and 1 and 5 years after surgery assessing three different levels of QOL. The main exposure was weight loss after SG, assessed as per cent excess body mass index (kg/m2) loss (%EBMIL). The Obesity-Related Problem (OP) scale was used to measure obesity-specific health-related QOL (HRQOL). Physical (PCS) and mental (MCS) composite summary scores of the Short Form 36 Health Survey were used to capture generic HRQOL and Cantril Ladder was used to assess overall QOL.ResultsAll HRQOL/overall QOL measures significantly improved at 1 year, followed by modest decline from 1 to 5 years after surgery. Greater %EBMIL 5 years after surgery was significantly associated with improvements in OP and PCS scores, but not with MCS and Cantril Ladder scores. Although significant (p<0.001) and clinically relevant improvements in HRQOL/overall QOL outcomes were observed at 5 years, scores were still below the general population norms.ConclusionMost patients undergoing SG experience substantial weight loss accompanied by statistically significant and clinically relevant long-term improvements in HRQOL/overall QOL. However, an important minority of patients still report low HRQOL/overall QOL 5 years after SG. Further research should aim to identify other factors that contribute to impaired QOL after bariatric surgery, even in the presence of successful weight control.

Reflux, Barrett’s Esophagus, and Esophageal Adenocarcinoma After Bariatric Surgery

2022 ◽  
pp. 263451612110683
Author(s):  
Benjamin Medina ◽  
Daniela Molena
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Sleeve Gastrectomy ◽  
Gastroesophageal Reflux ◽  
Barrett’S Esophagus ◽  
Esophageal Adenocarcinoma ◽  
Barrett's Esophagus ◽  
Treatment Options ◽  
Effective Treatment Option ◽  
Management Options

We present the case of a patient who developed esophageal adenocarcinoma after a previous laparoscopic sleeve gastrectomy. Bariatric surgery has emerged as the most effective treatment option for weight loss and obesity-related diseases; however, sleeve gastrectomy promotes gastroesophageal reflux and leads to Barrett’s esophagus in a substantial portion of patients. The natural history of Barrett’s esophagus in these patients is unknown, and active surveillance is recommended until the incidence of dysplasia and adenocarcinoma in this population is clarified. Management options for these patients include conversion to Roux-en-Y gastric bypass. Although esophagectomy in patients who have previously undergone sleeve gastrectomy may require an alternative conduit, the remnant stomach can be used in carefully selected patients. Here, we review the different weight loss procedures, their effect on gastroesophageal reflux disease and Barrett’s esophagus, and the treatment options for patients with esophageal cancer after sleeve gastrectomy. We report the use of preoperative coil embolization as a means of vascular preconditioning before successful use of a gastric conduit.

Comparative Effectiveness of Gastric Bypass and Vertical Sleeve Gastrectomy for Hypertension Remission and Relapse: The ENGAGE CVD Study

Hypertension ◽  
2021 ◽  
Author(s):  
Kristi Reynolds ◽  
Lee J. Barton ◽  
Anirban Basu ◽  
Heidi Fischer ◽  
David E. Arterburn ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Gastric Bypass ◽  
Sleeve Gastrectomy ◽  
Vertical Sleeve Gastrectomy ◽  
Variable Approach ◽  
Study Population ◽  
Instrumental Variable Approach

Weight loss is an effective strategy for the management of hypertension, and bariatric surgery is the most effective weight loss and maintenance strategy for obesity. The importance of bariatric surgery in the long-term management of hypertension and which operation is most effective is less clear. We compared the effectiveness of vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB) for remission and relapse of hypertension after surgery in the ENGAGE CVD cohort study (Effectiveness of Gastric Bypass Versus Gastric Sleeve for Cardiovascular Disease). Operations were done by 23 surgeons across 9 surgical practices. Hypertension remission and relapse were assessed in each year of follow-up beginning 30 days and up to 5 years postsurgery. We used a local instrumental variable approach to account for selection bias in the choice of VSG or RYGB. The study population included 4964 patients with hypertension at the time of surgery (n=3186 VSG and n=1778 RYGB). At 1 year, 27% of patients with RYGB and 28% of patients with VSG achieved remission. After 5 years, without accounting for relapse, 42% of RYGB and 43% of VSG patients had experienced hypertension remission. After accounting for relapse, only 17% of RYGB and 18% of VSG patients remained in remission 5 years after surgery. There were no statistically significant differences between VSG and RYGB for hypertension remission, relapse, or mean systolic and diastolic blood pressure at any time during follow-up.

Sign in / Sign up

Export Citation Format

Share Document